Table 4.
Response to Therapy (N = 38)
| Group | No. | OR |
CR* |
PR |
Median PFS (months) | |||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |||
| All patients | 38 | 31 | 82 | 21 | 55 | 10 | 26 | 25.6 |
| MCL | 10 | 8 | 80 | 7 | 70 | 1 | 10 | 21.9 |
| Nonblastoid | 8 | 6 | 75 | 5 | 63 | 1 | 13 | 35.9 |
| FL | 9 | 9 | 100 | 7 | 78 | 2 | 22 | 25.6 |
| MZL/LPL | 5 | 3 | 60 | 0 | 0 | 3 | 60 | 29.3 |
| CLL/SLL | 14 | 11 | 79 | 7 | 50 | 4 | 29 | 24.1 |
| Untreated | 22 | 18 | 82 | 12 | 55 | 6 | 27 | 25.1 |
| Relapsed | 16 | 13 | 81 | 9 | 56 | 4 | 25 | 25.6 |
| 1-hour dosing | 21 | 18 | 86 | 14 | 67 | 4 | 19 | 25.1 |
| Hybrid dosing | 17 | 13 | 76 | 7 | 41 | 6 | 35 | 25.6 |
Abbreviations: OR, overall response; CR, complete response; PR, partial response; MCL, mantle cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma; LPL, lymphoplasmacytic lymphoma; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; PFS, progression-free survival of responding patients.
*
Includes two patients with follicular lymphoma who had unconfirmed complete remissions.